Welcome to the Life Sciences Sector!

The Life Sciences Sector provides LES members in all areas of the life sciences industry, including but not limited to the Pharmaceutical, Biotech, BioMedical Devices, and Diagnostics & Genomics segments, with a place to network, share common experiences and learn from one another.

From the Life Sciences Sector

If you are here, then you most likely are interested to get plugged into what your LES Life Sciences Sector is up to and for that we thank you!

LES is a volunteer organization, and each of us is just like you - seeking how we might learn more about our industry and profession via education and networking As a member, you can be proud that the LSS is leading the charge within LES to raise the bar of quality and quantity of educational content and networking opportunities. And with your help, we hope to continue to make improvements.

There are many ways you can get involved. One of the easiest may be to participate in a workshop at an upcoming meeting.

While you are here, you might also wish to check out some of our other stuff. Under the link "LS Education and Content", you will find an excellent series of proprietary life science specific articles, written by some of the most thought provoking commentators on our industry. Under "LS News" you will find the latest of our quarterly email blasts to the LES Life Sciences Sector members.

In closing, we invite you to be active in your sector. If you have an idea or would like to volunteer, please contact the sector leaders.

Global BioPharma Royalty Rates and Deal Terms Survey

2009 Survey Highlights

A total of 184 completed surveys were incorporated into the final Global BioPharma Survey Report with over 40% of the reported deals from outside North America. This is a 20% increase in response from 2008.
Of those who responded, 39% were from pharmaceutical companies, 23% were from biotech companies, 12% were from academic institutions, 6% were from government, and 20% were from other organizations.
The survey report provides a detailed analysis on fixed royalties, tiered royalties, deal terms, valuation methods, and therapeutic areas.
Over 80% of the deals submitted had licenses that included the United States and close to 63% of licenses were considered “Global” in scope. Sixty-one percent of the deals were reported by the licensors and 82% of the deals were categorized as exclusive.

Click here for an executive summary of the survey, or click here to access the complete results. The full survey is an LES members only resource, so please login for access.

Click here to access information regarding the 2008 Global BioPharma Royalty Rates and Deal Terms Survey.

QUICK LINKS

JOIN LES NOW

LES Community Conversations

Learn and network with your peers without ever having to leave your office.
Read more...

Contact LS

Ideas? Complaints? Questions? Want to volunteer? Use this link to send us your thoughts.